Ionis Pharmaceuticals, Inc. (IONS)
NASDAQ: IONS · Real-Time Price · USD
35.63
+0.04 (0.11%)
At close: Dec 20, 2024, 4:00 PM
35.50
-0.13 (-0.36%)
After-hours: Dec 20, 2024, 6:32 PM EST
Ionis Pharmaceuticals Employees
Ionis Pharmaceuticals had 927 employees as of February 15, 2024. The number of employees increased by 131 or 16.46% compared to the previous year.
Employees
927
Change (1Y)
131
Growth (1Y)
16.46%
Revenue / Employee
$866,307
Profits / Employee
-$387,067
Market Cap
5.63B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Feb 15, 2024 | 927 | 131 | 16.46% |
Feb 16, 2023 | 796 | 136 | 20.61% |
Feb 16, 2022 | 660 | -97 | -12.81% |
Feb 18, 2021 | 757 | -60 | -7.34% |
Feb 20, 2020 | 817 | 80 | 10.85% |
Feb 20, 2019 | 737 | 190 | 34.73% |
Feb 20, 2018 | 547 | 112 | 25.75% |
Feb 21, 2017 | 435 | 7 | 1.64% |
Feb 19, 2016 | 428 | 38 | 9.74% |
Feb 17, 2015 | 390 | 86 | 28.29% |
Feb 17, 2014 | 304 | 16 | 5.56% |
Feb 11, 2013 | 288 | 7 | 2.49% |
Feb 13, 2012 | 281 | 11 | 4.07% |
Feb 14, 2011 | 270 | 20 | 8.00% |
Feb 10, 2010 | 250 | -50 | -16.67% |
Feb 10, 2009 | 300 | 0 | - |
Mar 1, 2008 | 300 | 26 | 9.49% |
Mar 5, 2007 | 274 | 16 | 6.20% |
Mar 3, 2006 | 258 | -45 | -14.85% |
Mar 3, 2005 | 303 | -154 | -33.70% |
Mar 3, 2004 | 457 | -66 | -12.62% |
Feb 28, 2003 | 523 | 89 | 20.51% |
Feb 28, 2002 | 434 | 131 | 43.23% |
Jan 31, 2001 | 303 | -49 | -13.92% |
Feb 25, 2000 | 352 | 6 | 1.73% |
Feb 26, 1999 | 346 | 8 | 2.37% |
Feb 27, 1998 | 338 | 51 | 17.77% |
Jan 31, 1997 | 287 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Elanco Animal Health | 9,800 |
RadNet | 8,441 |
Merit Medical Systems | 6,950 |
Stevanato Group | 5,634 |
Inspire Medical Systems | 1,011 |
Blueprint Medicines | 655 |
Cytokinetics | 423 |
Halozyme Therapeutics | 373 |
IONS News
- 1 day ago - FDA Approves Ionis Pharmaceuticals' Rare Genetic Disease Therapy to Lower High-Level Of Fat In Blood - Benzinga
- 2 days ago - TRYNGOLZA™ (olezarsen) approved in U.S. as first-ever treatment for adults living with familial chylomicronemia syndrome as an adjunct to diet - PRNewsWire
- 2 days ago - US FDA approves Ionis Pharma's genetic disorder drug - Reuters
- 6 weeks ago - Ionis to present at upcoming investor conferences - PRNewsWire
- 6 weeks ago - Ionis Pharmaceuticals, Inc. (IONS) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome - PRNewsWire
- 6 weeks ago - Ionis reports third quarter 2024 financial results - PRNewsWire
- 6 weeks ago - Ionis announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAE - PRNewsWire